Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives $30.00 Consensus PT from Brokerages

Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX) have been assigned an average rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and four have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $30.00.

Several equities research analysts have recently weighed in on KYTX shares. Wall Street Zen lowered Kyverna Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Wednesday, June 24th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Kyverna Therapeutics in a research note on Wednesday, June 3rd. Finally, JPMorgan Chase & Co. lowered their price target on Kyverna Therapeutics from $30.00 to $29.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 13th.

Kyverna Therapeutics Trading Down 8.3%

Shares of KYTX stock opened at $8.13 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 9.06 and a current ratio of 9.06. The firm has a fifty day moving average of $8.14 and a 200-day moving average of $8.43. Kyverna Therapeutics has a 52-week low of $3.27 and a 52-week high of $13.67. The stock has a market cap of $502.76 million, a price-to-earnings ratio of -2.77 and a beta of 1.93.

Kyverna Therapeutics (NASDAQ:KYTX) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.68) by $0.05. On average, equities research analysts forecast that Kyverna Therapeutics will post -2.7 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kyverna Therapeutics

Several large investors have recently made changes to their positions in the company. Legal & General Group Plc bought a new stake in Kyverna Therapeutics during the second quarter worth about $36,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Kyverna Therapeutics during the third quarter worth approximately $28,000. Federated Hermes Inc. raised its stake in shares of Kyverna Therapeutics by 36.6% in the fourth quarter. Federated Hermes Inc. now owns 20,705 shares of the company’s stock valued at $195,000 after acquiring an additional 5,547 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock valued at $61,000 after acquiring an additional 5,694 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares in the last quarter. Institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.